Patient reported outcomes from a Randomized Controlled Phase 3 Trial of Sarilumab in Polymyalgia Rheumatica

Sponsored by Sanofi

Mar 09, 2023 11:51 am

Author(s):

Vibeke Strand, Jennifer Sloane Lazar, Michael C Nivens, Jingdong Chao, Stefano Fiore, Angelika Giannelou, Lita Araujo, and Jerome Msihid

Abstract or description:

The poster reports the patient reported outcomes from the SAPHYR study. Patients treated with sarilumab 200mg Q2W + 14-week GC had clinically meaningful and robust improvement in patient reported outcomes compared to patients receiving placebo + 52-week GC.

More Virtual Posters

AbbVie March 2025

Real-world outcomes in patients with RA remaining on first-line TNFi

AbbVie March 2025

Long-term maintenance of response of an IL-23i in PsA

AbbVie March 2025

Time to first musculoskeletal response of an IL-23i in PsA

Sanofi RNL Poster

Effectiveness of Interleukin-6 Receptor Inhibitors versus Conventional Synthetic Immunomodulatory Therapy for Treatment of Frail Patients with Polymyalgia Rheumatica

Author(s):

Vibeke Strand, Jennifer Sloane Lazar, Michael C Nivens, Jingdong Chao, Stefano Fiore, Angelika Giannelou, Lita Araujo, and Jerome Msihid

Abstract or description:

The poster reports the patient reported outcomes from the SAPHYR study. Patients treated with sarilumab 200mg Q2W + 14-week GC had clinically meaningful and robust improvement in patient reported outcomes compared to patients receiving placebo + 52-week GC.

×